Cell Culture Market

The cell culture market is projected to reach USD 58.42 billion by 2031 from an estimated USD 33.07 billion in 2026, at a CAGR of 12.1% during the forecast period. The major factors driving the growth of the cell culture market include growing government support and funding for cell-based research, as well as the rising adoption of single-use technologies. Emerging cell culture technologies for producing cell-based viral vaccines also contribute to market growth. Furthermore, the growing popularity of monoclonal antibodies and biosimilars, alongside the increasing focus of key players on product launches, is expected to create further growth opportunities for the market in the coming years.

The global cell culture market is highly consolidated, with top players holding a major share, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), and Corning Incorporated (US). The market players have adopted various strategies, including new product launches, acquisitions, agreements, collaborations, and geographic expansions, to strengthen their position in the global cell culture market.

To know about the assumptions considered for the study download the pdf brochure

In May 2026, Thermo Fisher Scientific Inc. launched the Gibco CTS DynaXS Single-Use Bioreactor to support scalable cell therapy manufacturing.

In March 2026, Sartorius launched the Eveo Cell Therapy Platform, an integrated system designed to improve efficiency and scalability in autologous cell therapy manufacturing.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a leading provider of scientific solutions, offering a diverse range of products in the cell culture market, including cell culture media, reagents, supplements, and advanced technologies for cell growth and maintenance, enabling researchers to achieve optimal results in their experiments and bioproduction processes. Its leading position is attributed to its strong brand image and robust product portfolio. The company offers its products through well-established brands such as Gibco, Nunc, Countess, Dynabeads, and HyPerforma. It has focused on product launches, expansions, and acquisitions in the last three years. In April 2026, Thermo Fisher Scientific opened a flagship US Bioprocess Design Center in Massachusetts to support biologics development and scale-up activities.

Danaher (US)

Danaher is a leading life sciences and diagnostics innovator providing a wide range of products and services for medical, industrial, and commercial applications. With its strong global presence, Danaher Corporation is continually engaged in acquisitions and partnerships. For instance, in March 2026, Cytiva partnered with Yoshindo to support domestic biosimilar manufacturing in Japan by deploying the FlexFactory modular bioprocessing platform. Additionally, the company emphasizes expanding its capabilities in the cell culture market. In September 2024, Cytiva introduced its Innovation Hub in South Korea, covering around 6,100 square meters. This Innovation Hub included a manufacturing facility for manufacturing products needed in therapeutic development and a customer experience lab for product demonstrations.

Meck KGaA (Germany)

Merck KGaA offers a wide range of cell culture products, including media, sera, supplements, and reagents, catering to various research, bioprocessing, and clinical applications. They are widely used in biopharmaceutical manufacturing. The company has a strong international presence, with a wide distribution network and established relationships with research institutions and biotechnology & pharmaceutical companies worldwide. Merck focuses on expanding its presence in emerging markets due to the growing demand for cell culture products. This involves establishing partnerships, distribution networks, and manufacturing facilities in different regions. In October 2025, Merck partnered with Promega to co-develop 3D cell drug discovery technologies by combining Merck’s organoid and chemistry expertise with Promega’s assay and reporter platforms.

Market Ranking

The cell culture market is consolidated, with five main players collectively holding 60–65% of the total market share. Thermo Fisher Scientific Inc. leads with its expansive portfolio of sera, media, and cultureware, supported by a strong global distribution network. Merck KGaA leverages organic and inorganic growth strategies, including product launches, expansions, acquisitions, and collaborations, to expand its media and bioprocessing capabilities. Sartorius has rapidly gained ground through its robust bioreactor systems and media solutions, with a focus on automation and single-use technologies. Danaher, through Cytiva and Pall, strengthens its position with continuous investments in cell culture innovation and biomanufacturing infrastructure. Corning specializes in high-quality cell culture vessels and advanced surface treatments, with a growing focus on 3D cell culture and cell therapy applications.

The remaining 35–40% of the market is shared among other players. Market competition is driven by various factors, including product launches, cost-effectiveness, regulatory compliance, product innovation, and the growing demand for personalized medicine and drug discovery.

Related Reports:

Cell Culture Market by Consumables [Media, Sera, Reagents (Supplements, Buffers)], Vessels (Plates, Flask, Roller Bottle), Equipment (Bioreactor, Filtration, Incubators, Centrifuge), Application (mAbs, Vaccines, CGT), Competition - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]